Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
featured
Published in Oncology

Journal Scan / Research · June 30, 2019

3 vs 6 Months of Adjuvant FOLFOX or CAPOX for High-Risk Stage II and Stage III Colon Cancer

Annals of Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

Annals of Oncology
Three Versus Six Months Adjuvant FOLFOX or CAPOX for High Risk Stage II and Stage III Colon Cancer Patients: The Efficacy Results of Hellenic Oncology Research Group (HORG) Participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Project
Ann. Oncol 2019 Jun 22;[EPub Ahead of Print], J Souglakos, I Boukovinas, S Kakolyris, S Xynogalos, N Ziras, A Athanasiadis, N Androulakis, A Christopoulou, M Vaslamatzis, A Ardavanis, C Emmanouilides, I Bompolaki, C Kourousis, P Makrantonakis, C Christofyllakis, E Athanasiadis, N Kentepozidis, A Karampeazis, U Katopodi, A Anagnosopoulos, G Papadopoulos, E Prinarakis, A Kalisperi, D Mavroudis, V Georgoulias

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated